Festival of Genomics & Biodata-London 2024

Visit us at booth #74

Learn about our new 5-letter sequencing technology – duet multiomics solution +modC – and discover the combinatorial power of genetics and epigenetics.

24 January 2024
to 25 January 2024

ExCeL, London

About the event

We’re looking forward to seeing you at the 9th annual Festival of Genomics & Biodata in London on Wednesday 24th January and Thursday 25th January 2024.

The Festival is the annual get-together for the entire genomics and biodata community to discover, meet, learn and celebrate!

The Festival will bring you inspirational speakers, the latest research and clinical breakthroughs, cutting edge technology and incredible networking opportunities.

The Festival is designed to help you return to work, armed with dozens of new ideas and contacts, but also to keep you engaged, excited, and proud of the difference your efforts make for patients.

Refining your cancer research: generating more information from limited amounts of DNA

Tom Charlesworth, PhD

Director of Market Strategy & Corporate Development


January 24, 2024; 12:00-12:30, Pyramid Stage

Presentation abstract

During this session, you will learn how to;

  • Preserve Valuable Samples: Utilise samples as low as 10 ng of DNA for highly accurate modC.
  • C-to-T Mutation Detection: Simultaneously detect the most common type of genetic mutation (C-to-T) in the human genome and cancer.  
  • Whole Genome Investigation: Get simultaneous whole genome sequencing results with standard SNP detection and epigenetic marks with improved sensitivity and specificity.  
  • Allele-specific methylation: Attain phased results for allele-specific methylation (ASM) and maintain even genomic coverage.

The effect of Maturation Phase Transient Reprogramming on the genome and epigenome

Diljeet Gill


Altos Labs

January 24, 2024; 12:00-12:30, Pyramid Stage

Presentation abstract

The reprogramming process is capable of reversing multiple hallmarks of ageing, however complete reprogramming to iPSCs does not appear to be required for this as molecular features such as the epigenome are already rejuvenated by the maturation phase of iPSC reprogramming. We have developed a method called “maturation phase transient reprogramming”, where the factors required for reprogramming (OSKM) are expressed until this rejuvenation point and then withdrawn.


Applying MPTR to dermal fibroblasts from middle age donors, cells temporarily lose and then reacquire their fibroblast identity. Excitingly, this process substantially rejuvenates multiple cellular attributes including transcriptomic and DNA methylation ageing clocks. We are now investigating the effect of MPTR on the genome and epigenome in more detail and have performed 5-letter sequencing on fibroblasts after MPTR. We have found that transient reprogramming does not promote further mutations compared to cells that are not reprogrammed. In addition, 5L sequencing has enabled us to examine allele-specific methylation, which we found to be particularly increased on the X chromosome after MPTR. This sequencing technology is enabling us to better understand the safety of MPTR as well as the mechanisms that may be responsible for rejuvenation.

One sample. One workflow. One solution.

Here are the relevant biomodal resources for information. Find poster presentation information, case studies, interviews, and more.

Related resources

Attending from biomodal

Festival of Genomics London 2024

Get in touch

Cambridge Epigenetix is now biomodal